{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T09:03:06Z","timestamp":1770541386775,"version":"3.49.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006380","name":"Rehabilitation Research and Development Service","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006380","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.msard.2020.102249","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T11:46:05Z","timestamp":1591098365000},"page":"102249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Current and emerging therapeutics for neuromyelitis optica spectrum disorder: Relevance to the COVID-19 pandemic"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5346-8254","authenticated-orcid":false,"given":"Hesham","family":"Abboud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crystal","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indrani","family":"Kar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire Kaori","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crystal","family":"Sau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Serra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102249_bib0001","unstructured":"https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/immunocompetence.html#ref-43 accessed 4\/16\/2020."},{"key":"10.1016\/j.msard.2020.102249_bib0005","unstructured":"Clinicaltrials.gov. accessed April 16, 2020."},{"key":"10.1016\/j.msard.2020.102249_bib0002","unstructured":"Eculizumab (Soliris) in Covid-19 Infected Patients (SOLID-C19), 2014. Clinicaltrials.gov, accessed April 15, 2020."},{"key":"10.1016\/j.msard.2020.102249_bib0003","unstructured":"Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected2019."},{"key":"10.1016\/j.msard.2020.102249_bib0004","unstructured":"An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD, 2019. Clinicaltrials.gove\/accessed 4\/19\/2020."},{"key":"10.1016\/j.msard.2020.102249_bib0006","unstructured":"Eculizumab prescribing information 2020."},{"key":"10.1016\/j.msard.2020.102249_bib0007","unstructured":"Rituximab prescribing information2020."},{"key":"10.1016\/j.msard.2020.102249_bib0008","unstructured":"Mycophenolate mofetil prescribing information. 2020."},{"key":"10.1016\/j.msard.2020.102249_bib0009","unstructured":"https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/faq.html. Accessed April15, 2020."},{"issue":"2","key":"10.1016\/j.msard.2020.102249_bib0010","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2020.102249_bib0011","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1352458517740641","article-title":"Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study","volume":"25","author":"Agius","year":"2019","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2020.102249_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230869","article-title":"No evidence for hypogammaglobulinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with ravulizumab","volume":"15","author":"Alashkar","year":"2020","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.msard.2020.102249_bib0013","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2020.102249_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.msard.2020.102249_bib0015","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","article-title":"B lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102249_bib0016","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-020-0308-3","article-title":"COVID-19: immunopathology and its implications for therapy","author":"Cao","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.msard.2020.102249_bib0017","article-title":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells [published online ahead of print, 2020 May 18]","author":"Cao","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.msard.2020.102249_bib0018","unstructured":"Chinese Clinical Trial Registry. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19).Feb 13, 2020. http:\/\/www.chictr.org.cn\/."},{"issue":"9","key":"10.1016\/j.msard.2020.102249_bib0019","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.msard.2020.102249_bib0020","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"issue":"10206","key":"10.1016\/j.msard.2020.102249_bib0021","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.msard.2020.102249_bib0022","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1002\/art.37966","article-title":"Glucocorticoids suppress T cell function by upregulating microRNA 98","volume":"65","author":"Davis","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.msard.2020.102249_bib0023","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/rheumatology\/key361","article-title":"Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis","volume":"58","author":"Emery","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.msard.2020.102249_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rdc.2016.09.003","article-title":"Vaccines and disease-modifying antirheumatic drugs: practical implications for the rheumatologist","volume":"43","author":"Friedman","year":"2017","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.msard.2020.102249_bib0025","article-title":"Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19 [published online ahead of print, 2020 Apr 18]","volume":"41","author":"Giovannoni","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102249_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102073","article-title":"The COVID-19 pandemic and the use of MS disease-modifying therapies","volume":"39","author":"Giovannoni","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2020.102249_bib0027","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01753-18","article-title":"Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis","volume":"9","author":"Gralinski","year":"2018","journal-title":"mBio"},{"issue":"4","key":"10.1016\/j.msard.2020.102249_bib0028","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody\u2013associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2020.102249_bib0029","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan","volume":"395","author":"Huang","year":"2020","journal-title":"China. Lancet"},{"key":"10.1016\/j.msard.2020.102249_bib0030","article-title":"COVID-19 in persons with multiple sclerosis treated with ocrelizumab - a pharmacovigilance case series [published online ahead of print, 2020 May 16]","author":"Hughes","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2020.102249_bib0031","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch. Neurol."},{"issue":"14","key":"10.1016\/j.msard.2020.102249_bib0032","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2020.102249_bib0033","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102249_bib0034","first-page":"kez577","article-title":"Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry [published online ahead of print, 2019 Dec 17]","author":"Klein","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.msard.2020.102249_bib0035","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2020.102249_bib0036","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/aian.AIAN_365_19","article-title":"Plasma exchange as a first line therapy in acute attacks of neuromyelitis optica spectrum disorders","volume":"22","author":"Kumawat","year":"2019","journal-title":"Ann. Indian Acad. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2020.102249_bib0037","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.arcped.2014.08.018","article-title":"Traitement par tocilizumab\u202f: exp\u00e9rience d\u2019un centre de rhumatologie p\u00e9diatrique [Tocilizumab: experience in a French rheumatological pediatric center]","volume":"21","author":"Le Stradic","year":"2014","journal-title":"Arch. Pediatr."},{"key":"10.1016\/j.msard.2020.102249_bib0038","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13756-019-0475-9","article-title":"Pneumonia in hospitalized neurologic patients: trends in pathogen distribution and antibiotic susceptibility","volume":"8","author":"Lee","year":"2019","journal-title":"Antimicrob. Resist. Infect Control"},{"key":"10.1016\/j.msard.2020.102249_bib0039","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2020.102249_bib0040","article-title":"Clinical characteristics of 25 death cases with COVID-19: a retrospective review of medical records in a single medical center, Wuhan, China [published online ahead of print, 2020 Apr 3]","author":"Li","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.msard.2020.102249_bib0041","article-title":"Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19 [published online ahead of print, 2020 Apr 1]","volume":"214","author":"Ma","year":"2020","journal-title":"Clin. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2020.102249_bib0042","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol."},{"issue":"20","key":"10.1016\/j.msard.2020.102249_bib0043","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression [published online ahead of print, 2020 Mar 16]","volume":"S0140-6736","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2020.102249_bib0044","article-title":"Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: a case series of 60 patients from Madrid, Spain [published online ahead of print, 2020 May 7]","volume":"42","author":"Montero-Escribano","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2020.102249_bib0045","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2012-201950","article-title":"Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis","volume":"71","author":"Mori","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.msard.2020.102249_bib0046","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2020.102249_bib0047","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2008.092866","article-title":"Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study","volume":"68","author":"Nishimoto","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.msard.2020.102249_bib0048","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s12185-019-02635-9","article-title":"A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma","volume":"109","author":"Ohmachi","year":"2019","journal-title":"Int. J. Hematol."},{"issue":"7","key":"10.1016\/j.msard.2020.102249_bib0049","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102249_bib0050","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12974-015-0256-1","article-title":"Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype","volume":"12","author":"Pr\u00f6bstel","year":"2015","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102249_bib0051","article-title":"Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic [published online ahead of print, 2020 Feb 27]","author":"Prompetchara","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"10.1016\/j.msard.2020.102249_bib0052","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J. Autoimmun."},{"issue":"5","key":"10.1016\/j.msard.2020.102249_bib0053","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/art.30242","article-title":"In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment","volume":"63","author":"Roll","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.msard.2020.102249_bib0054","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3332\/ecancer.2020.1022","article-title":"Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence","volume":"14","author":"Russell","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.msard.2020.102249_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102195","article-title":"B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with Multiple Sclerosis during the early COVID-19 epidemic in Iran [published online ahead of print, 2020 May 13]","volume":"43","author":"Safavi","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2020.102249_bib0056","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.msard.2020.102249_bib0057","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bjh.15790","article-title":"Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis","volume":"185","author":"Soci\u00e9","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.msard.2020.102249_bib0058","article-title":"Italian Study Group on COVID-19 infection in multiple sclerosis. an Italian programme for COVID-19 infection in multiple sclerosis [published online ahead of print, 2020 Apr 30]","author":"Sormani","year":"2020","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2020.102249_bib0059","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5152\/eurjrheum.2016.16100","article-title":"Vaccination recommendations for adult patients with rheumatic diseases","volume":"3","author":"Tanr\u0131\u00f6ver","year":"2016","journal-title":"Eur. J. Rheumatol."},{"issue":"8","key":"10.1016\/j.msard.2020.102249_bib0060","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/art.30427","article-title":"Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections","volume":"63","author":"Tesfa","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.msard.2020.102249_bib0061","article-title":"The COVID-19 vaccine development landscape [published online ahead of print, 2020 Apr 9]","author":"Thanh Le","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.msard.2020.102249_bib0062","doi-asserted-by":"crossref","first-page":"402\u2010412","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2020.102249_bib0063","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"et al: Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.msard.2020.102249_bib0064","article-title":"An evidence based perspective on mRNA-SARS-CoV-2 vaccine development","volume":"26","author":"Wang","year":"2020","journal-title":"Med. Sci. Monit."},{"issue":"2","key":"10.1016\/j.msard.2020.102249_bib0065","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2020.102249_bib0066","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.msard.2020.102249_bib0067","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102249_bib0068","first-page":"eabc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques [published online ahead of print, 2020 May 20]","author":"Yu","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.msard.2020.102249_bib0069","doi-asserted-by":"crossref","first-page":"103\u2010107","DOI":"10.1016\/j.transci.2006.06.008","article-title":"Therapeutic plasma exchange in the treatment of neuroimmunologic disorders: review of 50 cases","volume":"36","author":"Y\u00fccesan","year":"2007","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.msard.2020.102249_bib0070","first-page":"ciaa344","article-title":"Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease","author":"Zhao","year":"2019","journal-title":"Clin. Infect. Dis."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820303254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820303254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:49:02Z","timestamp":1761900542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820303254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":70,"alternative-id":["S2211034820303254"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102249","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and emerging therapeutics for neuromyelitis optica spectrum disorder: Relevance to the COVID-19 pandemic","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102249","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102249"}}